Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polatuzumab vedotin + rituximab + gemcitabine + dexamethasone + cisplatin
- Development stage
- Unknown
- Lead developer
- UNC Lineberger Comprehensive Cancer Center
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
Polatuzumab vedotin + rituximab + gemcitabine + dexamethasone + cisplatin (PV-RGDP) is an investigational chemoimmunotherapy combination regimen being evaluated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL). The regimen integrates polatuzumab vedotin, an antibody-drug conjugate (ADC) targeting CD79b, with the standard R-GDP salvage chemotherapy backbone. Polatuzumab vedotin delivers the potent microtubule inhibitor monomethyl auristatin E (MMAE) directly to malignant B-cells, while rituximab provides anti-CD20 mediated immunotherapy. The chemotherapy components—gemcitabine, cisplatin, and dexamethasone—provide synergistic cytotoxic effects through DNA damage and anti-proliferative mechanisms. This specific combination is currently being studied in a Phase II clinical trial led by the UNC Lineberger Comprehensive Cancer Center to improve salvage therapy outcomes for both transplant-eligible and transplant-ineligible patients.
- Other names
- PV-RGDP regimen
02
Targets
B-cell antigen receptor complex-associated protein beta chainTUBB (Tubulin (alpha and beta subunits))CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on polatuzumab vedotin + rituximab + gemcitabine + dexamethasone + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polatuzumab vedotin + rituximab + gemcitabine + dexamethasone + cisplatin.